Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib versus crizotinib in ROS1-positive advanced or metastatic non-small cell lung cancer
2019-003859-11Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Entrectinib with Crizotinib (2 arms). Primary endpoint: Progression-free survival in patients with CNS metastases at baseline. Started Jun 2021; status: active.
02
Drugs
entrectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-003859-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003859-11.